Patents by Inventor Masayasu Yoshino
Masayasu Yoshino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10004739Abstract: The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.Type: GrantFiled: September 14, 2016Date of Patent: June 26, 2018Assignee: Astellas Pharma Inc.Inventors: Atsushi Suzuki, Makoto Asaumi, Kazuhisa Tsunoyama, Kouichi Nishimura, Akifumi Morinaka, Tomohiro Yamauchi, Masayasu Yoshino, Hiroaki Yoshizaki
-
Patent number: 9803024Abstract: [Problem] To provide an anti-human PAI-1 antibody for preventing or treating pulmonary fibrosis by binding to active human PAI-1 and inhibiting effects mediated by the active human PAI-1. [Means for Solution] The present inventors have investigated anti-PAI-1 antibodies and consequently have provided an anti-human PAI-1 antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 4.Type: GrantFiled: February 20, 2015Date of Patent: October 31, 2017Assignee: Astellas Pharma Inc.Inventors: Hirotsugu Tanaka, Masayasu Yoshino
-
Patent number: 9587015Abstract: Novel anti-human CTGF antibodies having excellent binding activity and/or neutralizing activity, as compared with conventional anti-human CTGF antibodies, are useful for treating various diseases in which human CTGF is involved in pathogenesis, including renal diseases such as chronic kidney disease and diabetic nephropathy.Type: GrantFiled: December 21, 2012Date of Patent: March 7, 2017Assignee: Astellas Pharma Inc.Inventors: Shoji Iwasaki, Ryuichi Moriya, Masayasu Yoshino, Koji Takakura
-
Publication number: 20160375023Abstract: The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.Type: ApplicationFiled: September 14, 2016Publication date: December 29, 2016Applicant: Astellas Pharma Inc.Inventors: Atsushi Suzuki, Makoto Asaumi, Kazuhisa Tsunoyama, Kouichi Nishimura, Akifumi Norinaka, Tomohiro Yamauchi, Masayasu Yoshino, Hiroaki Yoshizaki
-
Publication number: 20160369008Abstract: [Problem] To provide an anti-human PAI-1 antibody for preventing or treating pulmonary fibrosis by binding to active human PAI-1 and inhibiting effects mediated by the active human PAI-1. [Means for Solution] The present inventors have investigated anti-PAI-1 antibodies and consequently have provided an anti-human PAI-1 antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 4.Type: ApplicationFiled: February 20, 2015Publication date: December 22, 2016Applicant: Astellas Pharma Inc.Inventors: Hirotsugu TANAKA, Masayasu YOSHINO
-
Patent number: 9481911Abstract: [Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. [Means for Solution] The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.Type: GrantFiled: March 7, 2013Date of Patent: November 1, 2016Assignee: Astellas Pharma Inc.Inventors: Atsushi Suzuki, Makoto Asaumi, Kazuhisa Tsunoyama, Kouichi Nishimura, Akifumi Morinaka, Tomohiro Yamauchi, Masayasu Yoshino, Hiroaki Yoshizaki
-
Publication number: 20150031703Abstract: [Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. [Means for Solution] The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.Type: ApplicationFiled: March 7, 2013Publication date: January 29, 2015Applicant: Astellas Pharma Inc.Inventors: Atsushi Suzuki, Makoto Asaumi, Kazuhisa Tsunoyama, Kouichi Nishimura, Akifumi Morinaka, Tomohiro Yamauchi, Masayasu Yoshino, Hiroaki Yoshizaki
-
Publication number: 20140343258Abstract: [Problem] An object of the present invention is to provide an anti-human CTGF antibody having excellent binding activity and/or neutralizing activity, as compared with conventional anti-human CTGF antibodies, and means for preventing or treating various diseases in which human CTGF is involved in pathogenesis, including renal diseases such as chronic kidney disease and diabetic nephropathy, using the anti-human CTGF antibody. [Means for Solution] An anti-human CTGF antibody includes: a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 10; and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 4.Type: ApplicationFiled: December 21, 2012Publication date: November 20, 2014Applicant: ASTELLAS PHARMA INC.Inventors: Shoji Iwasaki, Ryuichi Moriya, Masayasu Yoshino, Koji Takakura
-
Publication number: 20070231812Abstract: A method of screening for an antidiabetic agent comprising (1) bringing a test substance into contact with a cell which overexpresses a polypeptide exhibiting an activity of suppressing insulin secretion under a high glucose concentration by an overexpression of the polypeptide in pancreatic ? cells, and comprising an amino acid sequence of SOCS-2 or a modified or homologous amino acid sequence thereof, under a high glucose concentration, and (2) measuring an amount of insulin secreted from the cell, or (1) bringing a test substance into contact with a cell transformed with a DNA fragment comprising a human SOCS-2 promoter sequence or a modified sequence thereof, (2) measuring an amount of expressed SOCS-2, and (3) selecting a substance which suppresses the amount of expressed SOCS-2, is disclosed.Type: ApplicationFiled: April 27, 2005Publication date: October 4, 2007Inventors: Mitsuo Itakura, Shoji Iwasaki, Masayasu Yoshino, Koichi Nishimuru